Telix Pharmaceuticals (NASDAQ:TLX) Stock Keeps Outperform Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Wedbush in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush's price objective would indicate a potential upside of 118.80% from the stock's current price.

Other equities analysts also recently issued reports about the company. Citigroup restated a "buy" rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Weiss Ratings upgraded Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, August 21st. Finally, Royal Bank Of Canada upgraded Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, September 21st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $20.50.

Telix Pharmaceuticals Stock Performance

Shares of Telix Pharmaceuticals stock traded down $1.11 during trading hours on Wednesday, hitting $10.06. The company's stock had a trading volume of 136,555 shares, compared to its average volume of 232,295. The business has a 50 day moving average price of $11.49 and a two-hundred day moving average price of $10.78. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Hedge Funds Weigh In On Telix Pharmaceuticals

Large investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its position in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after buying an additional 8,423 shares in the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals during the first quarter valued at approximately $120,000. WoodTrust Financial Corp bought a new position in Telix Pharmaceuticals during the third quarter valued at approximately $186,000. Private Advisor Group LLC boosted its stake in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after buying an additional 128,070 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the second quarter valued at approximately $1,731,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company's principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.